Skip to Content

Rib-X to Present at Ribosomes 2010 Conference

NEW HAVEN, Conn.--(BUSINESS WIRE)--May 3, 2010 - Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced that it will be presenting at the Ribosomes 2010 Conference, May 3-7, in Orvieto, Italy. The presentations include overviews on the design of next generation antibiotics and the Company's proprietary platform for unlocking the bacterial ribosome, allowing for the design and generation of novel antibiotics.



  • May 6, 4:00pm Ribosome Antibiotic Binding Paves Way for a New Family of Antibiotics

Brian Wimberly, Associate Director, Structure-Based Drug Discovery, Rib-X Pharmaceuticals, Inc.

This presentation will focus on the design of next generation macrolides (a family of antibiotics used to treat a wide range of bacterial infections), specifically, the company's RX-02 program of enhanced macrolides. Data presented will include a summary of research insights gained from proprietary crystal structures from Rib-X. Using these, the team is able to leverage previously unexploited portions of the ribosome to engineer macrolides that overcome resistance, extend antibacterial spectrum and drive oral efficacy in animal models of infection.



  • Enhanced Macrolides: Overcoming Resistance with a Novel Mechanism of Action

Eugene Skripkin, PhD, Senior Research Fellow, Structure-Based Drug Discovery, Rib-X Pharmaceuticals, Inc.

This poster discusses a new biochemical footprinting technique, called SHAPE, which demonstrates that Rib-X's enhanced macrolides bind in the intended region and by so doing, display a new mechanism of action for targeting the bacterial ribosome and overcoming antibiotic resistance mechanisms. Posters will be displayed during the entire meeting.

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. has an industry-leading pipeline of novel antibiotics targeting multidrug-resistant infections in significant and growing segments of the $25 billion antibiotics market. The Rib-X portfolio has four core programs including two late-stage product candidates, Delafloxacin and Radezolid, both potentially best-in-class antibiotics being developed in market-preferred intravenous and oral formulations for maximum flexibility. The foundation of the Rib-X product portfolio is its proven discovery technology, the Ribosome Antibiotic Binding "RAB" platform, using Nobel-prize-winning knowledge of ribosomal structure and mechanisms of antibiotic binding to create new chemical classes of antibiotics for a wide range of multidrug-resistant bacterial infections.

Contact: The Yates Network
Gina Nugent, 617-460-3579


Posted: May 2010